Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Amarantus BioScience Inc. News

    0,0001 $ 0,00% +0,00 $
    In : -    € | 11.04.24 15:30:05 Nasdaq OTC Other aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A14UX2
    ISIN: US02300U2050
    US-Symbol: AMBS
    Typ: Aktie

    Amarantus BioScience Inc. News

    27.04.22 - ACCESSWIRE
    Amarantus Signs Non-Binding Term Sheet to Divest Cutanogen Corporation in Exchange for the Extinguishment of Potential $21M+ in Liabilities
    Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto ...
    24.03.20 - PR Newswire
    Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-of-Care Screening and Confirmatory Testing Kits
    Coronavirus (COVID-19)-Focused Joint Venture Formed Between Emerald Organic and Todos Medical to Supply U.S. Market With Rapid Point-​of-Care Screening and Confirmatory ...
    25.10.19 - PR Newswire
    Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings
    Emerald Organic Products to License Therapeutics Portfolio from Amarantus Bioscience Holdings Portfolio includes treatments for Alzheimer's disease, ADHD, Parkinson's ...
    11.01.19 - PR Newswire
    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries PR Newswire
    11.01.19 - PR Newswire
    Amarantus gibt Partnerschaft mit IDEA Pharma zur Kommerzialisierung von Tochtergesellschaften bekannt
    Amarantus gibt Partnerschaft mit IDEA Pharma zur Kommerzialisierung von Tochtergesellschaften bekannt PR Newswire
    11.01.19 - PR Newswire
    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries
    Amarantus Announces Commercialization Partnership With IDEA Pharma for Subsidiaries PR Newswire
    01.12.17 - PR Newswire
    Amarantus Provides Comprehensive Corporate Update
    Amarantus Provides Comprehensive Corporate Update PR Newswire
    17.11.17 - PR Newswire
    Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants
    Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants PR Newswire
    27.09.17 - PR Newswire
    Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders
    Avant Diagnostics' Newly Appointed President & CEO Philippe Goix Delivered an Address to Shareholders PR Newswire
    18.07.17 - PR Newswire
    Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+
    Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in ...
    12.07.17 - PR Newswire
    Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform
    Avant Diagnostics Acquires Exclusive Option to License Genetic Health Solution Technology Platform PR Newswire
    17.04.17 - PR Newswire
    Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
    Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology PR Newswire
    05.04.17 - PR Newswire
    Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.
    Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc. PR Newswire
    27.02.17 - PR Newswire
    Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc.
    Amarantus Enters into a Letter of Intent to Acquire Certain Biotechnology Assets from SeD BioMedical Inc. PR Newswire
    10.02.17 - PR Newswire
    Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld
    Amarantus Announces Passing of Biotechnology Legend Dr. Joseph Rubinfeld PR Newswire
    08.08.16 - PR Newswire
    Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-Threatening Pediatric Severe Burns
    Amarantus Announces Publication of Human Clinical Data for Engineered Skin Substitute in the Treatment of Life-​Threatening Pediatric Severe Burns ESS reduces mortality and ...
    07.06.16 - PR Newswire
    Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville
    Amarantus Announces cGMP Manufacturing Readiness for Its Engineered Skin Substitute (ESS) Program at Lonza Walkersville Amarantus-​sponsored training for Phase 2 severe ...
    03.06.16 - PR Newswire
    Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results
    Amarantus Completes Sale of Diagnostics Division, Announces Fiscal Year 2015 and First Quarter 2016 Financial Results PR Newswire
    31.05.16 - PR Newswire
    OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference
    OTCQX and OTCQB Companies to Present at 2016 Marcum MicroCap Conference OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel ...
    27.05.16 - PR Newswire
    Amarantus Announces Upcoming Investor Presentations
    Amarantus Announces Upcoming Investor Presentations PR Newswire

    Newssuche

    Videos

    18.04.24
    Technical Trading: Gold mit weiterem Potenzial
    Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »